Common use of MAXIMUM CREDIT VALUE Clause in Contracts

MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Agreement in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 3 contracts

Sources: Manufacturing Services Agreement (Evoke Pharma Inc), Manufacturing Services Agreement (Evoke Pharma Inc), Manufacturing Services Agreement (Evoke Pharma Inc)

MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement [for any Product] in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] ]% of revenues (being payments of the Price) per Year received by Patheon under this Product Agreement, [***End of Product Agreement] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 2 contracts

Sources: Master Manufacturing Services Agreement (La Jolla Pharmaceutical Co), Master Manufacturing Services Agreement (Tetraphase Pharmaceuticals Inc)

MAXIMUM CREDIT VALUE. Patheon's ’s liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement for Product in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 2 contracts

Sources: Master Manufacturing Services Agreement (Acadia Pharmaceuticals Inc), Master Manufacturing Services Agreement (Acadia Pharmaceuticals Inc)

MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement for any Product in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 2 contracts

Sources: Product Agreement (ChemoCentryx, Inc.), Product Agreement (Recro Pharma, Inc.)

MAXIMUM CREDIT VALUE. Patheon's ’s liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement [for any Product] in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***[ ]% of revenues per Year to Patheon under this Product Agreement, up to a maximum of $[ ] [***] in the aggregate per Year. Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 2 contracts

Sources: Master Manufacturing Services Agreement (Horizon Pharma, Inc.), Master Manufacturing Services Agreement (Horizon Pharma, Inc.)

MAXIMUM CREDIT VALUE. Patheon's ’s liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement for any Product in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 2 contracts

Sources: Product Agreement (Osmotica Pharmaceuticals PLC), Product Agreement (Osmotica Pharmaceuticals LTD)

MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement for any Product in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] EXHIBIT A Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 1 contract

Sources: Master Manufacturing Services Agreement (Recro Pharma, Inc.)

MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement [for any Product] in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 1 contract

Sources: Master Manufacturing Services Agreement (Acadia Pharmaceuticals Inc)

MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement for Product in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 1 contract

Sources: Product Agreement (Acadia Pharmaceuticals Inc)

MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement [for any Product] in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***End of Product Agreement] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 1 contract

Sources: Master Manufacturing Services Agreement (Acadia Pharmaceuticals Inc)

MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement for the Product in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 1 contract

Sources: Product Agreement (TESARO, Inc.)

MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement [for any Product] in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 1 contract

Sources: Master Manufacturing Services Agreement (TESARO, Inc.)

MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement [for any Product] in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 1 contract

Sources: Master Manufacturing Services Agreement (Jazz Pharmaceuticals PLC)

MAXIMUM CREDIT VALUE. Patheon's ’s liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement [for any Product] in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] of revenues per Year to Patheon under this Product Agreement. Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 1 contract

Sources: Master Manufacturing Services Agreement (ChemoCentryx, Inc.)

MAXIMUM CREDIT VALUE. Patheon's ’s liability for Active Materials calculated in accordance with Section 2.2 of the Agreement in a Year will not exceed, in the aggregate, for the volumes indicated, the maximum credit value set forth below, expressed as a percentage of revenues to Patheon under this Agreement: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Confidential treatment requested; certain information omitted and filed separately with the SEC. Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 1 contract

Sources: Manufacturing Services Agreement (Chelsea Therapeutics International, Ltd.)

MAXIMUM CREDIT VALUE. Patheon's ’s liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement for the Product in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 1 contract

Sources: Product Agreement (Jaguar Animal Health, Inc.)

MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 1 contract

Sources: Product Agreement (Keryx Biopharmaceuticals Inc)

MAXIMUM CREDIT VALUE. Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement [for any Product] in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 1 contract

Sources: Master Manufacturing Services Agreement (Keryx Biopharmaceuticals Inc)

MAXIMUM CREDIT VALUE. Patheon's ’s liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE [***] [***] Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 1 contract

Sources: Product Agreement (Akebia Therapeutics, Inc.)

MAXIMUM CREDIT VALUE. Patheon's ’s liability for Active Materials calculated in accordance with Section 2.2 of the Agreement for any Product in a Year will not exceed, in the aggregate, the maximum credit value set forth below: PRODUCT MAXIMUM CREDIT VALUE Fidaxomicin [***] percent ([***] …]%) of Patheon’s revenues under this Agreement, in the aggregate per Year. Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 of the Agreement will be resolved in the following manner:

Appears in 1 contract

Sources: Manufacturing Services Agreement (Optimer Pharmaceuticals Inc)